WFH Bangkok 2004 Factor VIII-Von Willebrand Factor Inhibitors and Immune Tolerance Inhibitor Elimination Immune Tolerance Induction (ITI)

Slides:



Advertisements
Similar presentations
Implementing NICE guidance
Advertisements

INHIBITOR TO ANTIHEMOPHILIC FACTOR Djajadiman Gatot Division of Hematology Oncology Department of Child Health FMUI - CMGH.
Late Stabilization & Maintenance Phase of Treatment.
WFH Bangkok 2004 Factor VIII and von Willebrand Factor (VWF) VWF and Inhibitor Antibodies.
What a Bloody Mess! A/Professor Kent Robinson Senior Staff Specialist, Liverpool & Campbelltown Hospitals.
WFH Bangkok 2004 Factor VIII - Von Willebrand Factor Inhibitors and Immune Tolerance The Key Issue in Haemophilia A.
SUA
A single centre study of the efficacy of extracorporeal photopheresis in Acute Graft Versus Host Disease Lynne Watson Nottingham University Hospital NHS.
Treatment of congenital syphilis World Health Organization Guidelines for the Management of Sexually Transmitted Infections April 2001.
WFH Bangkok 2004 Octanate – Factor VIII with the Safety Factor VWF High Purity Plasma-Derived Factor VIII Double Virus Inactivated Haemophilia A Treatment.
© 2014 Direct One Communications, Inc. All rights reserved. 1 Recent Advances in Preventing Bleeding, Reducing Inhibitors, and Managing Acute Bleeding.
WFH Bangkok 2004 Self-Sufficiency of Plasma Derivatives.
© 2014 Direct One Communications, Inc. All rights reserved. 1 Hemophilia A and B: Disease Differences and the Use of Prophylactic Therapy Anna Chalmers,
Coagulation Disorders
Hemophilia What is Hemophilia? Hemophilia is an inherited bleeding disorder in which there is a deficiency or lack of factor VIII or factor IX clotting.
Richardson PG et al. Proc ASH 2013;Abstract 535.
Octaplex – The Modern PCC
Results of a Phase 2 Randomised, Open- Label, Study of Lower Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory.
Module 6: Treatment options. Module goal To enable participants understand the best current treatment options, factors that influence outcomes and potential.
Asthma Management Fine Tuning  Maximum control with minimum medication  Start with mild asthma and work up the scale (BTS/SIGN 2004)
CHILDHOOD SLE IN THE 21 ST CENTURY THE STATE OF THE ART How do we get the best possible outcome Thomas J. A. Lehman MD Chief, Division of Pediatric rheumatology.
Bridging Oral Anticoagulation with Low Molecular Weight Heparin: Experience in 367 Patients with Renal Insufficiency Heyder Omran, Giso von der Recke,
Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother to Child Transmission of HIV-1 in Thailand NEJM July 15, 2004 Lallemant et.
Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group,
Thymidine phosphorylase (TP) upregulation Dose- and time-dependent upregulation of TP in human colon cancer xenografts PaclitaxelDocetaxel.
Hemophilia U & I Inc., USA Payor Education Presentation Last Updated; January, 2012.
COMPLICATIONS OF HEMOPHILIA: INHIBITORS Nairobi, Kenya June 25, 2013.
FVIII PRODUCT USAGE IN CLINICAL SETTINGS TSEAC October 31, 2005 Mark Weinstein, Ph.D. Office of Blood Research and Review CBER, FDA.
Flucoral capsules Product knowledge. Pharmacokinetics of fluconazole Distribution of Fluconazole is extensive and even throughout tissues. The high polarity.
Dose Interruption/Reduction of Tyrosine Kinase Inhibitors in the First 3 Months of Treatment of CML Is Associated with Inferior Early Molecular Responses.
© 2014 Direct One Communications, Inc. All rights reserved. 1 Expanding Therapeutic Options for Hemophilia A and B: Results of Recent Clinical Trials Holleh.
PLASMA HALF LIFE ( t 1/2 ).  Minimum Effective Concentration (MEC): The plasma drug concentration below which a patient’s response is too small for clinical.
Methodology. Patients Women with progressive metastatic breast cancer that overexpressed HER2 who had not previously received chemotherapy for metastatic.
Randomisation* 2 : 1 Double blind *Randomisation was stratified on genotype (1a or 1b or other) and IL28B genotype (CC, CT or TT) N = 133 N = 260 W24W48.
CRITICAL APPRAISAL OF ARTICLE ON HARM. Among patients with acute rheumatic fever, will discontinuation of penicillin have adverse effects? Clinical question.
Which Early ST-Elevation Myocardial Infarction Therapy (WEST) Trial Paul W. Armstrong, WEST Steering Committee Published in The European Heart Journal.
A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.
The Studies of Oral Enoximone Therapy in Advanced Heart Failure ESSENTIALESSENTIAL Presented at The European Society of Cardiology Congress 2005 Presented.
Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM) 1 Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study.
CLINICAL PHARMACOKINETICS OF LIDOCAINE
Paraproteins and response assessments
Peri-Operative anticoagulation /antiplatelet therapy A Shift in Paradigm BMHGT04/29/09.
2Haemophilia Department, Royal Free Hospital, London, United Kingdom
1 EFFICACY OF SHORT COURSE AMOXICILLIN FOR NON-SEVERE PNEUMONIA IN CHILDREN (Hazir T*, Latif E*, Qazi S** AND MASCOT Study Group) *Children’s Hospital,
BIOPHARMACEUTICS.
Hemophilia Management: Joint Bleeds and Prophylaxis.
Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.
 Design Randomisation* 2 : 1 Double blind *Randomisation was stratified on genotype (1a vs 1b) and ILB28 genotype (CC or non-CC) N = 134 N = 257 W24W48.
507 Bacterial pathogenesis
Shrimati Shetty , Manali Bhave , Kanjaksha Ghosh
MULTIPLE DOSAGE REGIMEN
BACKGROUND  Acute severe ulcerative colitis (ASUC)  Medical emergency  I.V corticosteroid : mainstay management the past 40 years  One-third of patients.
Results from the International, Randomized Phase 3 Study of Ibrutinib versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)1.
Hemophilia 2009.
Scenario F/ 86 Autoimmune hypothyroidism since 2001
Alessandra Gennari, MD PhD
Warfarin Toxicity Treatment & Management
Mateos MV et al. Proc ASH 2013;Abstract 403.
Controlled drug release
Examining CV Effects of Basal Insulin Therapy
Clinical Pharmacokinetics
Tailoring Hemophilia Prophylaxis Therapy
EHL Technologies in Hemophilia Care
Successful Coronary Artery Bypass in Types 2M and 2N von Willebrand Disease  Mathieu Fiore, MD, PhD, Marie Tuffigo, MD, Véronique Cahoreau, MD, Pierre.
The Science of Gene Therapy for Hemophilia
IgG-Fc Fusion Proteins and Immunomodulation: What Does the Science Tell Us?
Thrombophilia in pregnancy: Whom to screen, when to treat
The efficacy and safety of omalizumab in pediatric allergic asthma
Current standard of care treatment protocols for LN induction therapy.
Late-Breaking Data on LDL-C Reduction
Presentation transcript:

WFH Bangkok 2004 Factor VIII-Von Willebrand Factor Inhibitors and Immune Tolerance Inhibitor Elimination Immune Tolerance Induction (ITI)

WFH Bangkok 2004 Immune Tolerance Induction (ITI) Induction of tolerance to FVIII in haemophiliacs with inhibitors (ITI) by regular administration of FVIII over a prolonged period of time began in Bonn, Germany, in the late 1970s Immunosupressive and immunomodulatory regimens were introduced in Malmö in the 1980s Treatment strategies vary according to the inhibitor level at time of treatment and the type of response on challenge

WFH Bangkok 2004 Immune Tolerance Induction (ITI) In inhibitors which have not been boostered, saturation of the inhibitor is possible and clinical levels of factor can be obtained Patients with high titre inhibitors may require so-called bypassing agents or extracorporeal removal of the inhibitor Treatment protocols vary considerably with regard to dosage, e.g. 300 FVIII IU/kg BW/day A high success rate is generally ascribed to ITI in haemophilia A with low/moderate response High-responding inhibitors are more difficult to overcome In haemophilia B, the success rate of ITI is considered to be lower than in haemophilia A

WFH Bangkok 2004 Immune Tolerance Induction (ITI): Protocols FVIII ITI ProtocolCharacteristics “Low dose” 25 FVIII IU/kg every other day, 1 – 12 months “Intermediate dose” 50 FVIII IU/kg daily, corticosteroids, 1 – 12 months High dose (Bonn Protocol) 200 – 300 FVIII IU/kg daily, APCC, several months to years High dose (Malmö Protocol) FVIII, immunosuppressives/ cytotoxics, IVIG, 1 – 2 months

WFH Bangkok 2004 ITI: Bonn Protocol 1st phase –100 IU FVIII/kg BW plus –40-60 U APCC/kg BW, every 12 hours 2nd phase –Inhibitor levels ~ 1 BU –150 IU FVIII/kg BW, daily 3rd phase –Inhibitor undetectable –FVIII prophylaxis: IU/kg BW, 3 x per week

WFH Bangkok 2004 ITI: Malmö Protocol 1st phase –Inhibitor levels > 10 BU reduced with immune adsorption using protein A sepharose 2nd phase –High dose FVIII, to sustain a measurable level –Cyclophosphamide, mg/kg BW, Iv for 2 days then –Cyclophosphamide, 2-3 mg/kg BW, orally for 8-10 days –Intravenous immunoglobulin (IVIG) 0.4g/kg BW/day for 5 days, beginning on the 4th day of FVIII treatment 3rd phase –Low dose FVIII prophylaxis

WFH Bangkok 2004 Outcome of ITI: Bonn Protocol Most patients treated with the Bonn protocol achieve inhibitor elimination Inhibitor levels peak within the first 1-2 months then fall rapidly Some patients require years of treatment

WFH Bangkok 2004 Outcome of ITI acc. to Bonn Protocol (1) Haemophilia 1995; 1: Patient Factor VIII Inhibitor Titre (BU) FVIII Dose (IU/kg/d) Time Between Inhibitor Detection and ITI Start Inhibitor Elimin- ation Time (months) StartMaximumEndMonths Exposure Days

WFH Bangkok 2004 Outcome of ITI acc. to Bonn Protocol (2) Haemophilia 1995; 1: Patient Factor VIII Inhibitor Titre (BU) FVIII Dose (IU/kg/d) Time Between Inhibitor Detection and ITI Start Inhibitor Elimin- ation Time (months) StartMaximumEndMonths Exposure Days No No

WFH Bangkok 2004 Outcome of ITI: Malmö Protocol In one study, 9/11 patients achieved inhibitor elimination after 2-3 weeks following the Malmö protocol Other outcomes (Info)

WFH Bangkok 2004 Haemophilia 1995; 1: Immune tolerance therapy in paediatric haemophiliacs with factor FVIII inhibitors: 14 years follow-up Kreuz W, Ehrenforth S, Funk M, Auerswald G, Mentzer D, Joseph-Steiner J, Beeg T, Klarmann D, Scharrer I, Kornhuber B

WFH Bangkok 2004 Criteria for Ending ITI Definition of success: –Inhibitor titre = 0 (3 consecutive tests) –Normal 12 hour recovery –Normal half-life for 6-8 weeks End ITI by continuous reduction of FVIII dosage by 10 % each week until normal prophylactic regime established No reappearance of inhibitor Haemophilia (1995), 1, 24-32

WFH Bangkok 2004 Criteria for Discontinuing ITI Discontinue ITI after 1 year if –Inhibitor titre no longer falling –Normal 12 hour recovery not achieved –Specific haemorrhagic problems arise Haemophilia (1995), 1, 24-32

WFH Bangkok 2004 Success Variables in ITI Dose of FVIII Maximum inhibitor titre Inhibitor titre at start of ITI Age at which ITI is carried out Time between inhibitor detection and start of ITI Interruption of therapy Haemophilia (1995), 1, 24-32

WFH Bangkok 2004 Factor VIII Dose in ITI High dose FVIII correlates with –Short inhibitor elimination time –Higher success rate Median Time for immune tolerance induction – 300 IU/kg/day3.0 months( ) – 200 IU/kg/day4.25 months( ) –< 100 IU/kg/day20 months( or failure) Results from > 200 patients included in the International Registry of Immune Tolerance Protocols Haemophilia (1995), 1, 24-32

WFH Bangkok 2004 Maximum Inhibitor Titre in ITI Patients with a maximum inhibitor titre higher than 600 BU may fail or take a very long time to achieve immune tolerance In patients with a maximum inhibitor titre of < 600 BU, there is no correlation between titre and time needed to achieve tolerance Haemophilia (1995), 1, 24-32

WFH Bangkok 2004 Inhibitor Titre and Age at Start of ITI Patients with higher inhibitor titres at the start of ITI require longer treatment The age of the patient at the beginning of therapy does not influence the outcome Haemophilia (1995), 1, 24-32

WFH Bangkok 2004 Inhibitor Detection and Start of ITI Times Results of ITI are influenced by the number of exposure days (ED) between initial detection of inhibitor and initiation of treatment Time to inhibitor eradication –< 14 ED months –14-21 ED months –15-21 ED months (or failure) Haemophilia (1995), 1, 24-32

WFH Bangkok 2004 Interruption of ITI In 5 patients in whom FVIII treatment was interrupted the outcome of therapy was significantly worse –Prolonged inhibitor elimination time (3 of 5) –Failure (2 of 5) Haemophilia (1995), 1, 24-32

WFH Bangkok 2004 Influence of Factor VIII Product on ITI Factor VIII concentrates containing von Willebrand factor (VWF) can influence the success of ITI (Info)